Hip osteoarthritis (ICD-10 M16 / ICD-11 FA00) is a clinical condition for which treatment selection requires careful alignment with current evidence. This protocol addresses the use of an oral pharmacological approach for this indication.
The regimen for this protocol includes duloxetine administered orally. Guideline support across the literature reflects nuanced considerations regarding its use in this context. The complete selection criteria, clinical decision points, and full treatment sequence are available in the structured protocol below.
DOI: 10.1016/j.rdc.2022.03.009.
Though duloxetine is approved for OA in some countries, there were only conditional or weak recommendations for its use across all guidelines, reflecting general concerns about efficacy and tolerability.
View source ↗